Skip to main content

Development of GPER agonists as a novel therapeutic option for pancreatic cancer

Project description

A new therapy could change the outcome for millions with pancreatic cancer

The tumour mass comprises a heterogeneous population of cancer cells and their surroundings. A variety of resident and infiltrating host cells, secreted factors and extracellular matrix are collectively known as the tumour microenvironment. In the case of pancreatic ductal adenocarcinoma (PDAC), pancreatic stellate cells (PSCs) are the main resident cells and the drivers of fibrosis. The fibrotic environment has a number of detrimental impacts including decreasing the effectiveness of therapies, impeding the immune response and helping the tumour grow. MechanoGPER has discovered a way to reprogram PSCs and thus the tumour microenvironment to recreate physiological conditions. Now researchers are developing ways to deliver therapies with the ultimate goal of changing the prognosis for PDAC.

Host institution

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
Net EU contribution
€ 150 000,00
Address
South Kensington Campus Exhibition Road
SW7 2AZ London
United Kingdom

See on map

Region
London Inner London — West Westminster
Activity type
Higher or Secondary Education Establishments
Other funding
No data

Beneficiaries (1)

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
United Kingdom
Net EU contribution
€ 150 000,00
Address
South Kensington Campus Exhibition Road
SW7 2AZ London

See on map

Region
London Inner London — West Westminster
Activity type
Higher or Secondary Education Establishments
Other funding
No data